These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15500913)

  • 1. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
    Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
    Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precise epitope mapping of malaria parasite inhibitory antibodies by TROSY NMR cross-saturation.
    Morgan WD; Frenkiel TA; Lock MJ; Grainger M; Holder AA
    Biochemistry; 2005 Jan; 44(2):518-23. PubMed ID: 15641776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate.
    Pizarro JC; Chitarra V; Verger D; Holm I; Pêtres S; Dartevelle S; Nato F; Longacre S; Bentley GA
    J Mol Biol; 2003 May; 328(5):1091-103. PubMed ID: 12729744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
    Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
    Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies.
    Lazarou M; Guevara Patiño JA; Jennings RM; McIntosh RS; Shi J; Howell S; Cullen E; Jones T; Adame-Gallegos JR; Chappel JA; McBride JS; Blackman MJ; Holder AA; Pleass RJ
    Infect Immun; 2009 Dec; 77(12):5659-67. PubMed ID: 19805526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory and neutral antibodies to Plasmodium falciparum MSP119 form ring structures with their antigen.
    Dekker C; Uthaipibull C; Calder LJ; Lock M; Grainger M; Morgan WD; Dodson GG; Holder AA
    Mol Biochem Parasitol; 2004 Sep; 137(1):143-9. PubMed ID: 15279960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4.
    Chang SP; Kayatani AK; Terrientes ZI; Herrera S; Leke RG; Taylor DW
    Malar J; 2010 Jan; 9():14. PubMed ID: 20070906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum.
    Li C; Wang R; Wu Y; Zhang D; He Z; Pan W
    Malar J; 2010 Apr; 9():94. PubMed ID: 20384992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
    Hui G; Hashimoto C
    Vaccine; 2007 Jan; 25(5):948-56. PubMed ID: 17023096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.
    Egan AF; Chappel JA; Burghaus PA; Morris JS; McBride JS; Holder AA; Kaslow DC; Riley EM
    Infect Immun; 1995 Feb; 63(2):456-66. PubMed ID: 7822010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
    Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
    East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.
    Uthaipibull C; Aufiero B; Syed SE; Hansen B; Guevara Patiño JA; Angov E; Ling IT; Fegeding K; Morgan WD; Ockenhouse C; Birdsall B; Feeney J; Lyon JA; Holder AA
    J Mol Biol; 2001 Apr; 307(5):1381-94. PubMed ID: 11292349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
    Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
    Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
    Murhandarwati EE; Wang L; de Silva HD; Ma C; Plebanski M; Black CG; Coppel RL
    Infect Immun; 2010 Feb; 78(2):680-7. PubMed ID: 19917716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.
    Hui GS; Gosnell WL; Case SE; Hashiro C; Nikaido C; Hashimoto A; Kaslow DC
    J Immunol; 1994 Sep; 153(6):2544-53. PubMed ID: 8077664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development.
    Moss DK; Remarque EJ; Faber BW; Cavanagh DR; Arnot DE; Thomas AW; Holder AA
    Infect Immun; 2012 Mar; 80(3):1280-7. PubMed ID: 22202121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.